Zhifei Longcom Recombinant COVID-19 Vaccine Receives Conditional Marketing Approval in Belarus2023-01-04

On January 3, local time, Zhifei longcom Recombinant COVID-19 Vaccine (CHO Cell) was approved for Conditional Marketing Approval by the Min...

Zhifei Longcom Recombinant COVID-19 Vaccine Receives Marketing Approval in Kenya2022-12-23

On December 22, the Company's Recombinant COVID-19 Vaccine (CHO Cell) was approved for marketing by the Pharmacy and Poisons Board (PPB) of...

Zhifei Longcom Passes EU QP Audit, An Acceleration in Zhifei’s International Strategic Layout2022-11-09

On November 8, 2022, the Recombinant COVID-19 Vaccine (CHO Cell) and the Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell) of An...

Zhifei’s Second-generation Recombinant COVID-19 Vaccine Starts International Clinical Trial2022-11-09

Source: Xinhua News Agency The launch ceremony of the international clinical trial of the Recombinant COVID-19 Omicron-Delta Variant Vaccin...

WHO Announces Updates to its Guidelines on Tests for the Diagnosis of TB Infection2022-10-08

On September 30, World Health Organization (WHO) published its updated consolidated guidelines on tuberculosis (TB) and the use of tests fo...